SEC Form 4 · accession 0001127602-15-027639
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairman & Co-CEO · Director
Period of report
Sep 24, 2015
Accepted (ET)
Sep 25, 2015 · 4:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 24, 2015 | M | 4,115 | $34.56 | A | 4,355 | D | |
| Common StockF3 | Sep 24, 2015 | S | 3,815 | $138.8091 | D | 540 | D | |
| Common StockF2 | Sep 24, 2015 | M | 5,547 | $30.75 | A | 6,087 | D | |
| Common StockF4 | Sep 24, 2015 | S | 1,500 | $138.3477 | D | 4,587 | D | |
| Common StockF5 | Sep 24, 2015 | S | 2,200 | $139.65 | D | 2,387 | D | |
| Common StockF6 | Sep 24, 2015 | S | 1,547 | $140.3427 | D | 840 | D | |
| Common StockF7 | Sep 24, 2015 | S | 300 | $141.14 | D | 540 | D | |
| Common Stock | Sep 24, 2015 | S | 300 | $139.19 | D | 240 | D | |
| Common Stock | holding | — | — | — | 166 | I | By Spouse | |
| Common Stock | holding | — | — | — | 625,031 | I | By Trusts |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options | $34.56 | Sep 24, 2015 | M | 4,115 | D | Dec 30, 2005 | Dec 30, 2015 | Common Stock | 4,115 | 32,935 | D |
| Stock Options | $30.75 | Sep 24, 2015 | M | 5,547 | D | Dec 26, 2009 | Dec 31, 2017 | Common Stock | 5,547 | 366,067 | D |
Explanation of responses
- F1This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- F2Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.
- F3This transaction was executed in multiple trades at prices ranging from $138.15 to $139.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $137.88 to $138.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $138.91 to $139.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $139.95 to $140.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $140.99 to $141.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.